Lucky Core Industries Limited (LCI): Pharma segment lifts FY25; core remained under pressure – By JS Research
Aug 22 2025
JS Global Capital
- Lucky Core Industries Limited (LCI) held its corporate briefing yesterday to discuss FY25 results and outlook. On a consolidated basis, EPS arrived at Rs25.2, reflecting a 4% YoY increase.
- Weak demand in soda ash and polyester weighed on topline growth, partly offset by strength in other business segments. Management guided payout ratio to remain at ~50% and reiterated focus on cost optimization in FY26. Company also remains debt free, providing room for value-added acquisitions.
- Pharma segment posted a major turnaround in FY25 with sales up 72% YoY to Rs21bn, including Rs7.2bn from the newly acquired Pfizer portfolio; with margins currently at 38% with management expecting this to remain the fastest-growing business in FY26.
Current:
Open:
Volume:
Change: ()
High:
Low:
52 Week High:
Vol Avg(12 m):
Free Float:
52 Week Low:
Market Cap:
Total Share:
Relative Strength Index (RSI)
RSI:
MACD Signals
MACD DAILY:
MACD WEEKLY:
Simple Moving Avg (SMA)
SMA(10):
SMA(30):
SMA(60):
SMA(200):
Performance
One Month:
Three Months:
Six Months:
Twelve Months:
Support & Resistance
Support 1:
Resistance 1:
Support 2:
Resistance 2:
High & Lows
Period
High
Low